F-Prime Capital

1upHealth, Inc. operates a health data aggregation and centralization platform that facilitates secure data transmission between health systems and consumer applications. Founded in 2017 and based in Boston, Massachusetts, the company's platform consolidates health data from various electronic medical record systems into a digital health record that users can control and share with their healthcare providers. It also enables providers to access and query up-to-date patient information from multiple connected health systems. Additionally, 1upHealth's platform allows software developers to obtain clinical data from various clinics and hospitals, enhancing the ability to monitor patient activity and automate secure data sharing. By connecting disparate data sources, 1upHealth aims to improve healthcare outcomes for patients while promoting interoperability within the healthcare ecosystem.

Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

Proximie Inc. is a health technology company based in Bedford, Massachusetts, that specializes in a telehealth platform designed for virtual surgical assistance. Founded in 2016 by Nadine Hachach-Haram, Proximie's platform enables surgeons to remotely observe and guide complex surgical procedures using augmented reality, artificial intelligence, and machine learning. This technology allows expert surgeons to connect with their peers globally, sharing knowledge and skills in real-time, regardless of their physical location. The platform is adaptable, compatible with various devices and software used in operating rooms, and can function effectively even in low bandwidth environments. Proximie aims to enhance surgical practices by democratizing access to expert guidance and fostering collaboration among medical professionals.

Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.

Funnel is a marketing analytics and reporting software that aims to streamline data collection for online advertisers and e-commerce companies. Founded in 2014 by Fredrik Skantze and Per Made, the company provides a platform that integrates with over 400 marketing and advertising sources. This allows businesses to automatically collect and structure advertising performance data, facilitating better decision-making regarding advertising spend and business growth. Funnel enables users to feed data into various tools, including Business Intelligence platforms, Data Warehouses, and visualization tools like Google Data Studio and Google Analytics. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B enterprises, mobile applications, and gaming companies. Funnel operates from its headquarters in Stockholm, with an additional office in Boston.

Zus Health is a healthcare technology company founded in 2020 in Watertown, Massachusetts, by Jonathan Bush. The company develops a healthcare data platform aimed at accelerating digital health initiatives. Its platform uniquely integrates health and non-health data, offering a comprehensive view of patients while facilitating the sharing of clinical and non-clinical information across different applications. This approach empowers healthcare professionals to create customized digital technologies and services that are more affordable and accessible, addressing the common barriers in the healthcare sector. Zus Health is focused on fostering innovation among a new generation of healthcare builders, striving to enhance the overall health experience.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Proximie Inc. is a health technology company based in Bedford, Massachusetts, that specializes in a telehealth platform designed for virtual surgical assistance. Founded in 2016 by Nadine Hachach-Haram, Proximie's platform enables surgeons to remotely observe and guide complex surgical procedures using augmented reality, artificial intelligence, and machine learning. This technology allows expert surgeons to connect with their peers globally, sharing knowledge and skills in real-time, regardless of their physical location. The platform is adaptable, compatible with various devices and software used in operating rooms, and can function effectively even in low bandwidth environments. Proximie aims to enhance surgical practices by democratizing access to expert guidance and fostering collaboration among medical professionals.

1upHealth, Inc. operates a health data aggregation and centralization platform that facilitates secure data transmission between health systems and consumer applications. Founded in 2017 and based in Boston, Massachusetts, the company's platform consolidates health data from various electronic medical record systems into a digital health record that users can control and share with their healthcare providers. It also enables providers to access and query up-to-date patient information from multiple connected health systems. Additionally, 1upHealth's platform allows software developers to obtain clinical data from various clinics and hospitals, enhancing the ability to monitor patient activity and automate secure data sharing. By connecting disparate data sources, 1upHealth aims to improve healthcare outcomes for patients while promoting interoperability within the healthcare ecosystem.

Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

RightHand Robotics, Inc. specializes in the manufacturing of robotic order-picking systems designed to enhance supply chain logistics and order fulfillment across various industries, including e-commerce, food handling, and flexible manufacturing. Founded in 2015, the company is headquartered in Cambridge, Massachusetts, with an additional office in Frankfurt, Germany. RightHand Robotics offers innovative solutions like the ReFlex SF, which features a 3D-printed palm equipped with advanced servos and compliant fingers, and the ReFlex TakkTile, a tactile sensor that aids in gentle object handling. Their technology enables robots to automatically grasp a wide range of items from bins and cases without the need for extensive data entry or parameter tuning, making their systems cost-effective and adaptable to changing business needs.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Funnel is a marketing analytics and reporting software that aims to streamline data collection for online advertisers and e-commerce companies. Founded in 2014 by Fredrik Skantze and Per Made, the company provides a platform that integrates with over 400 marketing and advertising sources. This allows businesses to automatically collect and structure advertising performance data, facilitating better decision-making regarding advertising spend and business growth. Funnel enables users to feed data into various tools, including Business Intelligence platforms, Data Warehouses, and visualization tools like Google Data Studio and Google Analytics. The company serves a diverse clientele, including e-commerce businesses, media agencies, brands, B2B enterprises, mobile applications, and gaming companies. Funnel operates from its headquarters in Stockholm, with an additional office in Boston.

Wellframe Inc. is a Boston-based company that specializes in digital care management solutions aimed at enhancing the relationship between health plans and their members. Founded in 2011, Wellframe develops a mobile patient engagement platform that utilizes real-time member-generated data and artificial intelligence to create personalized care protocols. Its offerings include a member mobile application for daily health tracking, a care team dashboard for prioritizing patient needs, and two-way communication solutions. The company also provides various services such as implementation, operational change management, and analytics. Additionally, Wellframe's digital health advocate solutions encompass intake assessments, concierge programs, and integrated workflows to enhance care management. The company's strategic partnerships with health plans nationwide allow it to deliver impactful health management solutions that empower patients and improve care outcomes.

Vendr, Inc. is a Boston-based company that specializes in a software-as-a-service (SaaS) platform designed to streamline the purchasing and renewal processes of software for businesses. Founded in 2018, Vendr offers a comprehensive suite of services including commercial negotiations, renewal management, and contract logistics. The platform empowers finance and procurement teams by providing access to extensive data from numerous transactions, enabling them to find suitable software, negotiate favorable prices, and manage renewals effortlessly. Vendr's commitment to simplifying SaaS procurement has positioned it as a leader in the industry, further enhanced by its recent acquisition of the SaaS management platform, Blissfully.

Firefly Health, Inc. is a Massachusetts-based company that develops an artificial intelligence-driven platform to connect patients with healthcare professionals. Founded in 2016, it focuses on providing primary healthcare services that emphasize accessibility and quality. The platform allows users to navigate their health while offering care for common conditions such as back pain, stomach flu, and women's health issues. Firefly Health utilizes a virtual-first approach, enabling patients to access live video appointments with primary care physicians without membership fees. This model facilitates continuous and intelligent care, empowering patients to make informed health choices and allowing clinicians to deliver consistent and proactive support.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, specializing in the development of technologies aimed at creating efficient, sustainable, and equitable mobility systems. As a spinoff from MIT, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and mobility-on-demand systems. Its team possesses extensive industrial and entrepreneurial expertise, encompassing areas such as manufacturing robots, urban design, and shared vehicle fleet management. Optimus Ride focuses on implementing self-driving technology in geofenced environments, utilizing advancements in sensor fusion, mapping, computer vision, and machine learning. This enables a wide range of transportation solutions, from commercial vessel operations to various transit options.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Valor Performance, Inc. is a Boston-based company that specializes in leadership and performance coaching. Established in 2017, it offers a digital platform designed to enhance the mental game and mindset of professionals, particularly managers and executives. The platform provides tailored programs, performance coaching, research-based exercises, and metrics for tracking progress. Additionally, Valor Performance emphasizes a scalable approach to professional training, ensuring a premium coaching experience through both digital resources and one-on-one interactions. The company's focus on coaching and analytics aims to help clients achieve and maintain peak performance in their professional roles.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Optimus Ride is a self-driving vehicle company located in Boston, Massachusetts, specializing in the development of technologies aimed at creating efficient, sustainable, and equitable mobility systems. As a spinoff from MIT, the company leverages over 30 years of interdisciplinary research in self-driving technologies, electric vehicles, and mobility-on-demand systems. Its team possesses extensive industrial and entrepreneurial expertise, encompassing areas such as manufacturing robots, urban design, and shared vehicle fleet management. Optimus Ride focuses on implementing self-driving technology in geofenced environments, utilizing advancements in sensor fusion, mapping, computer vision, and machine learning. This enables a wide range of transportation solutions, from commercial vessel operations to various transit options.

Valor Performance, Inc. is a Boston-based company that specializes in leadership and performance coaching. Established in 2017, it offers a digital platform designed to enhance the mental game and mindset of professionals, particularly managers and executives. The platform provides tailored programs, performance coaching, research-based exercises, and metrics for tracking progress. Additionally, Valor Performance emphasizes a scalable approach to professional training, ensuring a premium coaching experience through both digital resources and one-on-one interactions. The company's focus on coaching and analytics aims to help clients achieve and maintain peak performance in their professional roles.

Apellis Pharmaceuticals Inc., established in 2009, is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. The company specializes in developing therapeutic compounds that inhibit the complement system, focusing on autoimmune and inflammatory diseases with high unmet needs. Its lead product candidate, pegcetacoplan, is currently in Phase III trials for treating geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, and in Phase II trials for various kidney and blood disorders. Additionally, Apellis is developing APL-9 for preventing immune system activation during adeno-associated virus administration. The company collaborates with Swedish Orphan Biovitrum AB (publ) to advance pegcetacoplan for treating multiple rare diseases.

Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York. Founded in 2014, Buoy Health specializes in artificial intelligence-driven digital health solutions that assist individuals in managing their health and healthcare options. The company offers a personalized online healthcare chatbot, known as Buoy Assistant, which analyzes symptoms, facilitates initial triage, and provides treatment recommendations. This platform enables users to conduct real-time assessments of their symptoms while simplifying the navigation of the healthcare system. Additionally, Buoy Health provides resources for employees through its Buoy Dashboard, allowing them to research benefits, access wellness programs, and connect with in-network providers. The service is available 24/7, making self-diagnosis and healthcare navigation straightforward and accessible.

Wellframe Inc. is a Boston-based company that specializes in digital care management solutions aimed at enhancing the relationship between health plans and their members. Founded in 2011, Wellframe develops a mobile patient engagement platform that utilizes real-time member-generated data and artificial intelligence to create personalized care protocols. Its offerings include a member mobile application for daily health tracking, a care team dashboard for prioritizing patient needs, and two-way communication solutions. The company also provides various services such as implementation, operational change management, and analytics. Additionally, Wellframe's digital health advocate solutions encompass intake assessments, concierge programs, and integrated workflows to enhance care management. The company's strategic partnerships with health plans nationwide allow it to deliver impactful health management solutions that empower patients and improve care outcomes.

Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, that specializes in developing advanced intravenous (IV) infusion systems. Founded in 2001 and previously known as Fluidnet Corporation, Ivenix focuses on creating innovative solutions to improve infusion delivery in hospital settings. The company's flagship product is a next-generation infusion management system that employs pneumatic technology to accurately measure and control fluid flow, regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. This system not only simplifies the infusion process but also integrates with clinical information systems, enabling healthcare providers to manage patient infusion data effectively. By aiming to enhance the safety and efficiency of IV therapies, Ivenix is positioned to make a significant impact in the field of medical devices.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies that leverage its proprietary technology to maximize the effectiveness of existing immuno-oncology treatments while minimizing side effects outside the tumor. Its lead product, XTX201, is designed to induce immune activity specifically within tumors, demonstrating improved antitumor efficacy. Xilio Therapeutics aims to deliver significant improvements in patient outcomes by utilizing its platform to create a pipeline of novel therapies, including tumor-activated cytokines, antibodies, and immune cell engagers, all targeted to optimize therapeutic effects within the tumor microenvironment. Founded in 2015 and based in Waltham, Massachusetts, the company was previously known as Akrevia Therapeutics before rebranding in March 2020.

Codeship Inc. offers hosted continuous integration solutions that facilitate the building and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, Codeship provides a platform that automates the software deployment process, significantly shortening development cycles. This enables software companies to reduce the risk of bugs and accelerate innovation by streamlining the testing and release processes. Known for its fully customizable services, Codeship’s platform operates a B2D (business to developer) portal, catering to the needs of developers and businesses seeking efficient and secure integration services. In 2013, the company changed its name from Railsonfire Limited and has been a subsidiary of CloudBees, Inc. since February 2018.

Toast, Inc. is a Boston-based restaurant technology company that specializes in developing an all-in-one point-of-sale and restaurant management platform tailored for the food service and hospitality industries. Founded in 2011, Toast offers a cloud-based system designed specifically for restaurants, enabling functionalities such as tableside ordering, real-time reporting, online ordering, and labor management. The platform serves a diverse clientele, including restaurants, cafés, bars, and bakeries, and supports over 120,000 locations across the United States. Toast generates revenue through software subscription fees, transaction processing commissions, and additional services such as hardware installation and professional support. By facilitating payment transactions on its platform, Toast processed approximately $126 billion in gross volume in 2023, demonstrating its significant role in the restaurant technology landscape.

Codeship Inc. offers hosted continuous integration solutions that facilitate the building and deployment of Docker-based applications. Founded in 2011 and based in Boston, Massachusetts, with an additional office in Vienna, Austria, Codeship provides a platform that automates the software deployment process, significantly shortening development cycles. This enables software companies to reduce the risk of bugs and accelerate innovation by streamlining the testing and release processes. Known for its fully customizable services, Codeship’s platform operates a B2D (business to developer) portal, catering to the needs of developers and businesses seeking efficient and secure integration services. In 2013, the company changed its name from Railsonfire Limited and has been a subsidiary of CloudBees, Inc. since February 2018.

PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, that specializes in developing advanced intravenous (IV) infusion systems. Founded in 2001 and previously known as Fluidnet Corporation, Ivenix focuses on creating innovative solutions to improve infusion delivery in hospital settings. The company's flagship product is a next-generation infusion management system that employs pneumatic technology to accurately measure and control fluid flow, regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. This system not only simplifies the infusion process but also integrates with clinical information systems, enabling healthcare providers to manage patient infusion data effectively. By aiming to enhance the safety and efficiency of IV therapies, Ivenix is positioned to make a significant impact in the field of medical devices.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Surface Oncology, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cancer therapies. The company is advancing a pipeline of monoclonal antibodies, including SRF231, which inhibits CD47; NZV930, targeting CD73; SRF617, aimed at CD39; SRF388, which targets interleukin 27; and SRF813, focused on CD112R. Additionally, Surface is exploring earlier-stage programs that address critical elements of the tumor microenvironment, such as regulatory T cells and natural killer cells. The company has established collaborations with notable partners, including Novartis Institutes for Biomedical Research for cancer therapy development and Merck Sharp & Dohme Corp. to assess the safety and efficacy of combining SRF617 with KEYTRUDA, an anti-PD-1 therapy. Founded in 2014 and headquartered in Cambridge, Massachusetts, Surface Oncology aims to create conditions that enhance anti-tumor immune responses through its targeted approaches in cancer immunotherapy.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Kensho Technologies, Inc. specializes in analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. Founded in 2012 and headquartered in Cambridge, Massachusetts, with additional offices in New York, Virginia, and California, Kensho develops financial analytics software that enables scalable analytics solutions for commercial entities. Its offerings include Kensho Applied Mind, an AI software that enhances decision-making by addressing complex financial inquiries in natural language. The company also operates a national security division known as Koto. As of April 2018, Kensho operates as a subsidiary of S&P Global Inc.

ownCloud, Inc. develops a universal file access platform that allows organizations to host their own file sync and share solutions in their data centers or on cloud storage, ensuring compliance with regulatory requirements. The company's flagship product, ownCloud, is an open-source software solution that facilitates data access, management, and sharing across various devices, including desktop and mobile platforms. This self-hosted server enables users to collaborate securely with internal and external parties without relying on public cloud storage. ownCloud serves a diverse range of industries, including financial services, healthcare, government, and education, providing solutions for file synchronization, federated cloud sharing, and integration with SharePoint. Founded in 2011, ownCloud, Inc. is headquartered in Lexington, Massachusetts, with an international presence in Germany.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Semma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative cell therapies for patients with Type 1 diabetes. Founded in 2014, the company is dedicated to creating a transformative treatment that addresses the need for insulin injections by generating functional, insulin-producing beta cells through a proprietary method licensed from the laboratory of Professor Douglas Melton. Semma Therapeutics aims to combine these engineered cells with advanced devices to offer a potential replacement for the missing beta cells in diabetic patients, eliminating the need for immunosuppression. The company's ongoing research seeks to bring this novel therapeutic option to clinical settings, ultimately improving the lives of individuals living with diabetes.

Flywire is a payments enablement and software company headquartered in Boston, Massachusetts, that specializes in providing secure payment solutions for various industries, including education and healthcare. The company leverages its proprietary global payments network, an advanced payments platform, and industry-specific software to facilitate complex transactions for over 4,000 clients worldwide. Flywire supports a diverse range of payment methods, allowing transactions in more than 140 currencies across 240 countries and territories. Its solutions aim to streamline the process of receiving reconciled domestic and international payments, enhancing cost-effectiveness and efficiency for its clients. The majority of Flywire's revenue is generated from the Americas, reflecting its strong presence in the region.

Kensho Technologies, Inc. specializes in analytics, artificial intelligence, machine learning, and data visualization systems tailored for global banks and investment institutions. Founded in 2012 and headquartered in Cambridge, Massachusetts, with additional offices in New York, Virginia, and California, Kensho develops financial analytics software that enables scalable analytics solutions for commercial entities. Its offerings include Kensho Applied Mind, an AI software that enhances decision-making by addressing complex financial inquiries in natural language. The company also operates a national security division known as Koto. As of April 2018, Kensho operates as a subsidiary of S&P Global Inc.

Cloudant is a provider of distributed database-as-a-service (DBaaS) that enables developers of web and mobile applications to concentrate on product development rather than database management and scaling. Founded in 2008 in Cambridge, Massachusetts, by three MIT physicists, Cloudant emerged from their need for improved tools to handle large data sets from the Large Hadron Collider. The company built a globally scalable, fault-tolerant data layer using Apache CouchDB, catering to the needs of fast-growing applications. Cloudant now manages and serves operational data for thousands of developers and hundreds of customers worldwide, offering robust data tools for loading, storing, analyzing, and distributing application data.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

Cloudant is a provider of distributed database-as-a-service (DBaaS) that enables developers of web and mobile applications to concentrate on product development rather than database management and scaling. Founded in 2008 in Cambridge, Massachusetts, by three MIT physicists, Cloudant emerged from their need for improved tools to handle large data sets from the Large Hadron Collider. The company built a globally scalable, fault-tolerant data layer using Apache CouchDB, catering to the needs of fast-growing applications. Cloudant now manages and serves operational data for thousands of developers and hundreds of customers worldwide, offering robust data tools for loading, storing, analyzing, and distributing application data.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Blueprint Medicines Corporation is a biopharmaceutical company that specializes in developing small molecule kinase inhibitors aimed at treating genomically defined cancers and rare diseases. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on personalized cancer therapies by leveraging its proprietary chemical library and advanced research capabilities. Its key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, and pralsetinib for RET-altered non-small cell lung cancer and medullary thyroid carcinoma. Additionally, Blueprint Medicines is advancing BLU-263, a KIT inhibitor for mast cell disorders, and fisogatinib for advanced hepatocellular carcinoma, both currently in clinical trials. The company’s innovative approach seeks to address the molecular drivers of cancer and resistance mechanisms, aiming to enhance treatment effectiveness and patient outcomes. Blueprint Medicines has established collaborations with several pharmaceutical companies to further its research and development efforts.

Iora Health, Inc. is a healthcare provider based in Boston, Massachusetts, established in 2010. The company specializes in primary care services, focusing on delivering personalized and relationship-based care to patients across the United States. Each patient is assigned a dedicated physician and a health coach, who maintain regular communication through various channels, including email, text, and video. Iora Health employs a team-based approach that includes physicians, nurse practitioners, nurses, behavioral health specialists, and health coaches, all supported by a proprietary technology platform that enhances population health management. The organization also offers educational programs, such as group visits, to help patients achieve their health goals and navigate the healthcare system without barriers.

FoldRx Pharmaceuticals, Inc. is focused on the discovery and development of disease-modifying drug therapies targeting diseases associated with protein misfolding and amyloidosis. Established in 2003 and based in Cambridge, Massachusetts, the company has advanced clinical programs aimed at treating genetic neurologic and cardiovascular disorders, specifically transthyretin-associated amyloidoses involving polyneuropathy and cardiomyopathy. Additionally, FoldRx is engaged in research programs addressing conditions such as Parkinson's disease and cystic fibrosis. By developing therapies that address the accumulation of misfolded proteins, the company aims to enhance treatment options for healthcare professionals dealing with these complex disorders.

BIKAM Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. BIKAM's research centers on small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins within the retina. Their lead product is an orally active pharmacological chaperone that targets misfolded rod opsin, which is implicated in retinitis pigmentosa, helping to correct its trafficking to the rod cell surface and outer segment. Through its innovative approach, BIKAM Pharmaceuticals strives to provide new treatment options for patients suffering from these serious retinal conditions.

FoldRx Pharmaceuticals, Inc. is focused on the discovery and development of disease-modifying drug therapies targeting diseases associated with protein misfolding and amyloidosis. Established in 2003 and based in Cambridge, Massachusetts, the company has advanced clinical programs aimed at treating genetic neurologic and cardiovascular disorders, specifically transthyretin-associated amyloidoses involving polyneuropathy and cardiomyopathy. Additionally, FoldRx is engaged in research programs addressing conditions such as Parkinson's disease and cystic fibrosis. By developing therapies that address the accumulation of misfolded proteins, the company aims to enhance treatment options for healthcare professionals dealing with these complex disorders.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Ironwood Pharmaceuticals, Inc. is a healthcare company dedicated to the development and commercialization of gastrointestinal products. It is best known for its flagship product, linaclotide, which is used to treat adults with irritable bowel syndrome with constipation and chronic idiopathic constipation. This medication is marketed as LINZESS in the United States and CONSTELLA in Canada and the European Union. Additionally, Ironwood is advancing other treatments, such as MD-7246, an oral pain reliever for abdominal pain associated with gastrointestinal diseases, and IW 3718, a formulation in Phase III clinical trials for gastroesophageal reflux disease. The company has established collaboration agreements with Allergan and AstraZeneca for the development of linaclotide in several regions, and a license agreement with Astellas Pharma for its use in Japan. Founded in 1998 and formerly known as Microbia, Inc., Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.